Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utility of intra-abdominal pressure and point-of-care ultrasound to guide diuretic therapy in acute heart failure (ABDOPOCUS-HF)
2024-512901-22-00Phase 3Authorised
- Sponsor
- IIS Aragón
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of furosemide and hydrochlorothiazide in Acute Heart Failure (AHF) (2 arms), sponsored by IIS Aragón. Primary endpoint: Absence of congestion at 72 hours. Planned start Aug 2024; status: authorised.
02
Drugs
furosemidehydrochlorothiazide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2024-512901-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512901-22-00.